Arthur E. Frankel

Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia

Eytan M. Stein, Courtney D. DiNardo, Daniel A. Pollyea et al. · Blood · 2017 · 1.5K citations · Full text

Medicine, Hematology, Oncology +13

Pivotal Phase III Trial of Two Dose Levels of Denileukin Diftitox for the Treatment of Cutaneous T-Cell Lymphoma

Elise A. Olsen, Madeleine Duvic, Arthur E. Frankel et al. · Journal of Clinical Oncology · 2001 · 610 citations

Medicine, Oncology, Pharmacology +17

Autophagy regulates selective HMGB1 release in tumor cells that are destined to die

J. Thorburn, Henrick Horita, Jasmina S. Redzic et al. · Cell Death and Differentiation · 2008 · 272 citations · Full text

Life Sciences, Cancer Biology, Oncology +13

Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients

Arthur E. Frankel, Jung Hee Woo, Chul Ahn et al. · Blood · 2014 · 230 citations · Full text

Life Sciences, Immunology, Oncology +14

Phase I clinical study of diphtheria toxin-interleukin 3 fusion protein in patients with acute myeloid leukemia and myelodysplasia

Arthur E. Frankel, Jen-Sing Liu, David A. Rizzieri et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2008 · 153 citations

Medicine, Hematology, Pharmacology +16